These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 6124197)

  • 21. [Alpha-1 inhibition. Knowledge and prospectives].
    Meyer N
    Ann Cardiol Angeiol (Paris); 1990 Dec; 39(10 ( Pt 2)):625-7. PubMed ID: 1983164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin.
    Awan NA; Beattie JM; Evenson ME; Needham KE; Mason DT
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S176-80. PubMed ID: 6175836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and hemodynamic improvement of congestive heart failure by long-term vasodilator therapy with postjunctional alpha 1-adrenoceptor blockade.
    Bertel O; Bühler FR; Burkart F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S181-6. PubMed ID: 6175837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure.
    Ajayi AA; Sofowora GG; Balogun MO
    Int J Cardiol; 1996 Dec; 57(2):173-6. PubMed ID: 9013270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of alpha-receptor blockade with prazosin in advanced chronic congestive heart failure.
    Lui HK; Awan NA; Mason DT
    Herz; 1983 Apr; 8(2):65-70. PubMed ID: 6303929
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of ibopamine plus prazosin in congestive heart failure.
    Naidoo DP; Rocke A; Mitha AS
    S Afr Med J; 1998 Feb; 88 Suppl 1():C25-31. PubMed ID: 9542492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure.
    Colucci WS; Holman BL; Wynne J; Carabello B; Malacoff R; Grossman W; Braunwald E
    Am J Med; 1981 Jul; 71(1):75-80. PubMed ID: 6113759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of selective alpha blockers. Hemodynamics and effects on lipid levels.
    Reid JL; Elliott HL; Vincent J; Meredith PA
    Am J Med; 1987 Jan; 82(1A):15-20. PubMed ID: 3799697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
    Awan NA; Lee G; DeMaria AN; Mason DT
    Am Heart J; 1981 May; 101(5):541-7. PubMed ID: 7223594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. For the patient. New treatments for heart failure in Black people. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.
    Ajayi AA; Sofowora GG; Adigun AQ; Asiyanbola B
    Ethn Dis; 2003; 13(1):150. PubMed ID: 12723027
    [No Abstract]   [Full Text] [Related]  

  • 35. Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.
    Good AP; Unverferth DV; Leier CV
    Cardiovasc Drugs Ther; 1988 Jan; 1(5):529-34. PubMed ID: 2908715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
    Desch CE; Magorien RD; Triffon DW; Blanford MF; Unverferth DV; Leier CV
    Am J Cardiol; 1979 Nov; 44(6):1178-82. PubMed ID: 495512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prazosin and peripheral renin activity in severe arterial hypertension].
    Rubio Páez D; Porqué E; de Montero EP; Domínguez M; Silva H
    Cardiology; 1980; 66 Suppl 2():26-38. PubMed ID: 6116541
    [No Abstract]   [Full Text] [Related]  

  • 38. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of prazosin as initial antihypertensive therapy.
    Okun R
    Am J Cardiol; 1983 Feb; 51(4):644-50. PubMed ID: 6829427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure.
    Chatterjee K; Rubin SA; Ports TA; Parmley WW
    Am J Med; 1981 Jul; 71(1):140-6. PubMed ID: 7246571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.